Farnesoid X receptor (FXR) is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue which regulates a wide variety of target genes critically involved in the control of bile acid synthesis and transport, lipid metabolism and glucose homeostasis. Targeting FXR is a very promising strategy for the treatment of several liver diseases such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC) and biliary atresia.

Currently, there is no approved therapy for NASH available. The discovery of FXR agonists offers new hope to stop or even reverse the progression of these diseases.